drugset / Trial / NCT04730856

Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)

NCT04730856

Completed 311 enrolled Hospital Universitario Infanta Leonor
RandomizedSingle-groupOpen-labelDiagnostic

Summary

The main objective is to evaluate the efficacy and safety of three doses of tinzaparin (prophylactic, intermediate and therapeutic) in hospitalized patients with COVID-19 pneumonia.

Timeline

Start
2021-02-01
Primary completion
2021-10-20
Completion
2021-12-20

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tinzaparin Other / unclassified 100 iu/kg Subcutaneous
Comparator Tinzaparin Other / unclassified 175 iu/kg Subcutaneous
Comparator Tinzaparin Other / unclassified 4500 iu Subcutaneous